Biogen, UPenn ally in gene therapies for multiple indications
Under a multi-year agreement potentially worth up to $2bn in research funding, option payments, and milestones, Biogen Inc. and the University of Pennsylvania are teaming up to develop gene therapies and advance gene therapy and gene editing technologies, mostly focused on ophthalmic, musculoskeletal, and neurological diseases.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.